Abstract 1144 Elucidating novel pro-apoptotic consequences of an altered sphingolipidome in endocrine therapy-resistant breast cancer

Endocrine Therapy (ET)-resistant breast cancer remains a clinical problem, with approximately 40% of patients experiencing disease relapse. In our previous study, we demonstrated that preclinical models of ET-resistant breast cancer have an altered sphingolipid profile. This is characterized by decreased levels of endogenous ceramides across multiple models of ET resistance. The ET-resistant models are also more sensitive to ceramide-induced cell death compared to their ET-sensitive counterparts suggesting a functional significance of the low levels of ceramides.